Navigation Links
Onyx Pharmaceuticals Reports 2008 First Quarter Results
Date:5/6/2008

of March 31, 2008, the company had cash, cash equivalents, and short and long-term marketable securities of $456.6 million compared to $469.7 million at December 31, 2007. This decrease was primarily due to cash used in operations for the three months ended March 31, 2008.

Conference Call with Management Today

Onyx's management will host a teleconference and webcast to provide an update on Nexavar and discuss first quarter 2008 financial results. The event will begin at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) on May 6, 2008. Interested parties may access a live webcast of the presentation on our website at:

http://www.onyx-pharm.com/wt/page/event_calendar

or by dialing 630-691-2760 and using the passcode 21488196. A replay of the presentation will be available on the Onyx website or by dialing 630-652-3044 and using the passcode 21488196 approximately one hour after the teleconference concludes. The replay will be available through June 6, 2008.

About Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer by changing the way cancer is treated(TM). The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar(R) (sorafenib) tablets, a small molecule drug. Nexavar is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in non-small cell lung cancer, melanoma, breast cancer and other cancers. For more information about Onyx, visit the company's website at: http://www.onyx-pharm.com.

Nexavar(R) (sorafenib) tablets is a registered trademark of Bayer HealthCare Pharmaceuticals Inc.

This news release contains "forward-looking statements" of Onyx within
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Involution Studios , a healthcare ... new infographic, Understanding Ebola . The goal ... easy to follow informative tool for anyone wanting to ... and prevention. , "As the news has spread in ... outbreak represents not only a healthcare crisis with global ...
(Date:10/22/2014)... Currently offering a comprehensive portfolio ... Weighing, Rice Lake, and Ohaus, Pipette.com has added ... Sartorius CPA Semi-Micro Balance is ideal for lab ... user-friendly laboratory balance. , Sartorius is a global ... balances are well known for their high performance, ...
(Date:10/22/2014)... 2014 Physicians Choice Laboratory Services ... menu, which enables healthcare providers to individualize therapeutic ... evidence-based results, healthcare providers are better able to ... while minimizing risks for adverse drug reactions and ... the FDA [1] more than 2.2 million adverse ...
(Date:10/22/2014)... --  Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... and diseases, announced today that the U.S. Patent and ... a composition of matter patent application that covers the ... This is Synthetic Biologics, first allowed patent application directly ... the Company,s extensive C. difficile patent estate. ...
Breaking Biology Technology:Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4
... On June 19 and 20 at the Drake Hotel ... real estate, legal, engineering and due diligence providers gathered ... on the small and middle markets ($10 million to ... such as "maximizing the value of your brand and ...
... Madison, Wis . - In a merging of complementary companies, ... new Vitamin D products, has acquired Proventiv Therapeutics, LLC, of ... $25 million in venture capital from Canadian and American investors. ... of Bone Care International , which was acquired last ...
... and natural gas have sparked a race to make transportation ... and gasoline containing ethanol are starting to make an impact ... has also fueled a race to find new sources for ... many modern plastics, drugs, and fuels. Behind the scenes, American ...
Cached Biology Technology:Some great insights into the current Mergers & Acquisitions Market 2Some great insights into the current Mergers & Acquisitions Market 3Some great insights into the current Mergers & Acquisitions Market 4Some great insights into the current Mergers & Acquisitions Market 5Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO 2Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO 3UW prof turns sugar into diesel fuel, chemicals 2UW prof turns sugar into diesel fuel, chemicals 3
(Date:10/15/2014)... The Ebola virus is spreading rapidly and to an ... experienced in the past and the virus shows a ... been recorded before. For this reason, the German National ... of Science and Engineering, and the Union of the ... statement on the Ebola epidemic today. , In the ...
(Date:10/15/2014)... 44th Rosenstiel Award for Distinguished Work in Biomedical Science ... mechanisms of genomic instability and its implications for the ... alumnus to win the Rosenstiel Award; the first, Rod ... is the Charles A. Janeway Professor of Pediatrics and ... investigator at the Howard Hughes Medical Institute at Boston ...
(Date:10/14/2014)... Cancer Research shows SIRT6—a protein known to inhibit ... development of skin cancers by turning on an enzyme ... cells. , Previously considered protective, SIRT6 is part of ... regulate genomic stability and prevent some of the genetic ... which can lead to cancer. This study, in the ...
Breaking Biology News(10 mins):Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2
... World leaders have made pitiful progress on their guarantee to ... a paper published today (Friday 15th June) in Science ... researchers have reviewed commitments made by governments to protect the ... over the past 20 years. At the World ...
... found a surprising connection between a key DNA-repair process and ... and other chronic conditions. The discovery promises to open up ... could ultimately yield novel treatments for a wide variety of ... it goes against current dogma about the role of DNA ...
... the Instituto Andaluz de Ciencias de la Tierra and other ... published in the prestigious journal Reviews of Modern Physics ... different countries has published the most comprehensive study ever done ... important contemporary issues in a field of research that is ...
Cached Biology News:A sea of broken promises 2Scientists tie DNA repair to key cell signaling network 2Spanish scientist participate in the most comprehensive study ever done on ice 2
... Thermo Savant SpeedVac Concentrators set the standard ... SC110A SpeedVac uses a combination of centrifugal force, ... a single run., SC110A comes equipped with:, , ... chemical compatibility , ...
... Savant SpeedVac™ Concentrators set the standard for sample ... SpeedVac with large chamber uses a combination of ... samples in a single run. , SC210A comes ... for long lasting chemical compatibility ...
... (for aqueous, other low volatility and noxious ... to specific applications of molecular biology and ... heat-labile samples. The RC systems can be ... and a wide selection of rotors (eliminating ...
... Jouan RC Standard Bio for vacuum ... of molecular biology and biochemistry for rapid ... RC systems can be expanded with pumps, ... selection of rotors (eliminating sample loss by ...
Biology Products: